Oral water-soluble contrast for malignant bowel obstruction: open label pilot study.

Autor:	Wan Bahrum WFIB; Palliative and Supportive Care, Mater Misericordiae Ltd, South Brisbane, Queensland, Australia.; Department of Palliative Care, St Vincent's Private Hospital, Brisbane, Queensland, Australia., Hardy J; Palliative and Supportive Care, Mater Misericordiae Ltd, South Brisbane, Queensland, Australia.; Mater Research - University of Queensland, South Brisbane, Queensland, Australia., Foster K; Palliative and Supportive Care, Mater Misericordiae Ltd, South Brisbane, Queensland, Australia karyn.foster@mater.org.au.; Mater Research - University of Queensland, South Brisbane, Queensland, Australia., Good P; Palliative and Supportive Care, Mater Misericordiae Ltd, South Brisbane, Queensland, Australia.; Department of Palliative Care, St Vincent's Private Hospital, Brisbane, Queensland, Australia.; Mater Research - University of Queensland, South Brisbane, Queensland, Australia.
Jazyk:	angličtina
Zdroj:	BMJ supportive & palliative care [BMJ Support Palliat Care] 2024 Jan 08; Vol. 13 (e3), pp. e794-e797. Date of Electronic Publication: 2024 Jan 08.
DOI:	10.1136/bmjspcare-2021-003444
Abstrakt:	Objectives: Malignant bowel obstruction (MBO) is a common, challenging condition in advanced cancer. Oral water-soluble contrast medium (Gastrografin) has been used in the management of MBO without quality studies of its effectiveness and safety. The purpose of this study was to evaluate the feasibility, effectiveness and adverse effects of Gastrografin in patients with MBO and to assess feasibility of the study protocol. Methods: A prospective, interventional, single-arm, open label study of Gastrografin across two centres. Patients with unresolved inoperable MBO after 24 hours of conservative medical management were given a single dose of 100 mL of oral Gastrografin. Results: Over 33 months, 69 individual patients were screened. Of the 20 recruited, 17 completed study assessments (85%). MBO resolved in 10 of 17 patients (59%). Gastrografin passed through to the rectum in 14 patients (78%). The most common adverse effects were diarrhoea, vomiting, nausea and abdominal pain. Conclusions: Patient recruitment took longer than anticipated, but the study protocol is feasible. Gastrografin was found to be a relatively effective option for the treatment of MBO. An adeqautely powered randomised controlled trial is needed to formally assess the efficacy and safety of Gastrografin© in MBO. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu